Regeneron's cholesterol drug war heats up with lawsuit over Amgen's 'illegal' bundling scheme

Since their PCSK9 drugs to lower bad cholesterol won FDA approvals a month apart in the summer of 2015, Amgen and Regeneron have waged a war for supremacy in the market—with the California-based drugmaker a decided winner.

But has Amgen crossed the line with its marketing strategy for Repatha? In an antitrust lawsuit filed in Delaware Friday, Regeneron says Amgen has “sought by hook or by crook” to exclude its cholesterol drug Praluent from the market to “entrench Repatha’s monopoly position.”